Clinical Trial Update: A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of Burfiralimab plus a DMARD in moderate to severe rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Burfiralimab (Burfiralimab)
• DMRD (Disease-modifying Antirheumatic Drug) (DMRD)

Snippet

Sponsor: ImmuneMed, Inc. | Conditions: Moderate to Severe Rheumatoid Arthritis | Phase 2 | Status: UNKNOWN